DIM和PSA降低:阻止芳香化为前列腺健康:一个案例报告
Danielle Arnold1, Oscar Coetzee2, Allyson LaGrutta3
1Adjunct Professor, Purdue Global University; Lead Clinician, The Source Functional Nutrition, Albuquerque, NM.
Alternative therapies in health and medicine
|October 7, 2025
概括
迪因多利甲 (DIM) 补充剂降低了前列腺特异性抗原 (PSA) 和改善了荷尔蒙失衡患者的水平. 这表明DIM可以通过调节雌激素代谢来支持前列腺健康.
科学领域:
- 内分泌学 在内分泌学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 营养学科学 营养学科学
背景情况:
- 一名78岁的男性患者呈现出前列腺特异性抗原 (PSA) 的升高和水平的下降.
- 对潜在的前列腺病理和患者对活检的不情愿的担忧导致了功能医学方法.
- 人们怀疑荷尔蒙失衡是导致患者病情的因素.
研究的目的:
- 为了检查二醇甲 (DIM) 对PSA水平和荷尔蒙平衡的影响.
- 探索DIM使用与荷尔蒙变化之间的潜在因果关系.
- 评估功能医学方法在管理前列腺健康生物标志物的有效性.
主要方法:
- 停止服用降胆固醇补充剂.
- 在3个月内每天服用100毫克的DIM-EvailTM.
- 监测PSA和水平 (总和自由水平).
主要成果:
- 在三个月内,PSA水平从4.6降至2.4 ng/mL.
- 总丸激素从436增加到615 ng/dL.
- 自由丸激素水平也显示出显著的增加.
结论:
- 像DIM这样的有针对性的营养药干预措施显示出调节激素代谢的潜力.
- DIM可能是支持前列腺健康和解决荷尔蒙失衡的可行选择.
- 需要进一步进行更大规模的临床研究来验证这些发现.
相关概念视频
Disorders of the Male Reproductive System
4.0K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
4.0K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
1.4K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.4K
Atherosclerosis III: Management
319
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
319
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
557
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
557


